Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
COVID Symptoms |
Schedule a COVID vaccine or booster appointment:
Log in to myPennMedicine or call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Sees patients age 18 and up
Sees patients age 18 and up
Recognized by America's Top Doctors, 2008, 2010 - 2018
Recognized by Best Doctors in America, 2009, 2010, 2013 - 2018
Recognized annually in Philadelphia magazine's Top Docs issues, 2009 - 2021
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Penn Presbyterian Medical Center
Pavilion for Advanced Care, First Floor
51 N. 39th Street
Philadelphia, PA 19104
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Maturing role of immunotherapy in advanced NSCLC.Role of targeted agents in oncogene-driven NSCLCNew strategies in SCLCUnique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLCUnderserved populations, including older patients and those with compromised performance status.Novel therapeutic venues in thoracic and head and neck cancer
Marmarelis ME, Yang YX, Hwang WT, Mamtani R, Singh A, Ciunci C, Aggarwal C, Cohen RB, Langer CJ.: Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. Clin Lung Cancer. S1525-7304 (22): 00005-5,2022.
Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC.: Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 16 (11): 1883-1892,2021.
Nimgaonkar V, Aggarwal C, Berman AT, Gabriel P, Shulman LN, Kucharczuk J, Roy M, Bauml JM, Singh AP, Cohen RB, Langer CJ, Marmarelis ME.: Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic. BMC Cancer 21 (1): 1094,2021.
Kish JA, Zhang Q, Langer CJ, Nguyen-Tân PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, Shenouda G, Harris J, Le QT.: The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. J Geriatr Oncol. 12 (6): 937-944,2021.
Sun L, Hsu M, Cohen RB, Langer CJ, Mamtani R, Aggarwal C.: Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol. 7 (6): 937-939,2021.
Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Langer C, Senan S, Spigel D, Rydén A, Zhang Y, O'Brien C, Dennis PA, Antonia SJ.: Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 17 (10): 1165-1184,2021.
Sun L, Marmarelis ME, Langer CJ.: Systemic Therapy for Mutation-Driven NSCLC. Semin Radiat Oncol. 31 (2): 140-148,2021.
Thompson JC, Carpenter EL, Silva BA, Rosenstein J, Chien AL, Quinn K, Espenschied CR, Mak A, Kiedrowski LA, Lefterova M, Nagy RJ, Katz SI, Yee SS, Black TA, Singh AP, Ciunci CA, Bauml JM, Cohen RB, Langer CJ, Aggarwal C.: Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis Oncol. 5 : 2021.
Predina JD, Haas AR, Martinez M, O'Brien S, Moon EK, Woodruff P, Stadanlick J, Corbett C, Frenzel-Sulyok L, Bryski MG, Eruslanov E, Deshpande C, Langer C, Aguilar LK, Guzik BW, Manzanera AG, Aguilar-Cordova E, Singhal S, Albelda SM.: Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. Mol Ther. 29 (2): 658-670,2021.
Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ.: Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 151 : 30-38,2021.
Division of Hematology OncologyPerelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-2063400 Civic Center Boulevard
Patient appointments: 800-789-7366